Join the 'HIV Infection' group to help and get support from people like you.
HIV Infection Blog
Related terms: Acquired Immune Deficiency Syndrome, Acquired Immunodeficiency Syndrome (AIDS), Acute HIV Infection, Acute Retroviral Syndrome, AIDS, AIDS-Related Complex, Chronic Symptomatic HIV Infection, HIV Infection, Acute, HIV Seroconversion Syndrome, Human Immunodeficiency Virus Infection, Primary HIV Infection, HIV, ARC, Acquired Immunodeficiency Syndrome, HIV/AIDS
| Tweet |
FDA Approves Prezcobix (darunavir and cobicistat) for HIV-1 Infection in Adults
Posted 2 days 16 hours ago by Drugs.com
TITUSVILLE, N.J., Jan. 29, 2015 /PRNewswire/ – Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced the U.S. Food and Drug Administration (FDA) has approved Prezcobix (darunavir 800 mg/cobicistat 150 mg) tablets, an HIV-1 protease inhibitor combined with a CYP3A4 inhibitor, for the treatment of human immunodeficiency virus (HIV-1) in combination with other antiretroviral agents for treatment-naive and treatment-experienced adults with no darunavir resistance-associated substitutions.[1] Prezcobix is a once-daily, fixed-dose antiretroviral combination tablet containing 800 mg of darunavir, marketed as PREZISTA® in the United States, and 150 mg of cobicistat, a pharmacokinetic enhancer or "boosting" agent, developed and marketed as Tybost® by Gilead Sciences, Inc., taken orally with other HIV-1 medications and with food. "Additional options remain an i ... Read more
Related support groups: HIV Infection, Cobicistat, Darunavir
FDA Approves Evotaz (atazanavir and cobicistat) for HIV-1 Infection in Adults
Posted 2 days 16 hours ago by Drugs.com
PRINCETON, N.J. – January 29, 2015 --(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved Evotaz (atazanavir 300 mg and cobicistat 150 mg) tablets in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. Evotaz is coformulated to be one pill, once-daily, combining the protease inhibitor atazanavir, which is marketed as Reyataz (atazanavir 200 mg/300 mg) capsules, and cobicistat, a pharmacokinetic enhancer marketed by Gilead Sciences, Inc. Today’s approval offers patients living with HIV an innovative treatment option that delivers proven suppression (HIV-1 RNA 70mL/min, a mean baseline plasma HIV-1 RNA of 4.8 log10 copies/mL, and a mean baseline CD4+ cell count of 352 cells/mm. At 48 weeks, 85% of patients in the Evotaz arm achieved HIV-1 RNA levels of Read more
Related support groups: HIV Infection, Atazanavir, Cobicistat
Depo-Provera Linked to Higher HIV Risk, Researchers Find
Posted 9 Jan 2015 by Drugs.com
FRIDAY, Jan. 9, 2015 – The injectable birth control Depo-Provera is associated with an increased risk of HIV infection in women, according to a review of research in Africa. Women who receive the so-called "birth control shot" have about 40 percent higher odds of becoming infected with HIV, compared to women using some other form of birth control or no birth control at all, researchers reported. However, the review's authors said that the increased risk does not outweigh the contraceptive benefits of Depo-Provera, particularly in the African nations where these studies took place. Banning Depo-Provera would leave many women in developing countries without immediate access to alternative contraceptive options, which would likely lead to more unintended pregnancies, said lead author Lauren Ralph, an epidemiologist at the University of California, Berkeley, School of Public Health. ... Read more
Related support groups: Provera, Depo-Provera, HIV Infection, Medroxyprogesterone, Depo-Provera Contraceptive, depo-subQ provera 104, Depo-Sub Q Provera, Amen, Cycrin, Curretab
HIV Tied to Worse Hearing in Older Adults
Posted 29 Dec 2014 by Drugs.com
FRIDAY, Dec. 26, 2014 – A new study finds that adults with HIV tend to have worse hearing than those not infected with the AIDS-causing virus. Researchers led by Peter Torre, of San Diego State University, assessed the hearing of 262 men averaging 57 years of age, and 134 women averaging 48 years of age. A total of 117 of the men and 105 of the women were HIV-positive. While the study couldn't prove cause-and-effect, Torre's team found that people with HIV tended to have worse lower- and higher-frequency hearing. This was true even after the researchers took other factors into account, such as a person's long-term exposure to powerful HIV-suppressing antiviral drugs or their HIV "viral load." "To our knowledge, this is the first study to demonstrate that HIV-positive individuals have poorer hearing across the frequency range after many other factors known to affect hearing have been ... Read more
Related support groups: HIV Infection, Hearing Loss
Is HIV Becoming Less Contagious?
Posted 3 Dec 2014 by Drugs.com
MONDAY, Dec. 1, 2014 – New research in Africa suggests that the AIDS virus is getting smarter about evading the immune system while evolving into a less contagious and less lethal infection overall. In the country of Botswana, at least, "anyone who is newly infected now with HIV is less likely to suffer disease than if they had been infected 20 or 30 years ago," said study co-author Philip Goulder, a research immunologist with the University of Oxford in England. "If this process continues, HIV will cause less and less disease." The research has caveats. It relies on research from just two countries, both in Africa, and might not apply to the rest of the world. And some of its findings are based on mathematical models of how HIV, the virus that causes AIDS, is evolving. Still, the study is "good news," Goulder contended. Thanks to natural selection, some viruses actually evolve to make ... Read more
Related support groups: HIV Infection
Most Americans With HIV Don't Have Virus Under Control, CDC Says
Posted 25 Nov 2014 by Drugs.com
TUESDAY, Nov. 25, 2014 – Fewer than one-third of Americans living with HIV had the virus under control in 2011, with many either not receiving regular medical care or unaware they carry the virus, a new U.S. study finds. The U.S. Centers for Disease Control and Prevention study estimates that 70 percent of the 1.2 million Americans living with HIV in 2011 did not have their virus under control, even though combination drug therapies can effectively suppress the virus before it can develop into full-blown AIDS. A combination of indifference and lack of access to medical care appeared to outweigh ignorance as a driving factor in cases of uncontrolled HIV, researchers from the CDC's National Center for HIV/AIDS reported Tuesday. "For people living with HIV and AIDS, it's not enough to know – you also have to go for health care," said CDC Director Dr. Tom Frieden at a Tuesday news ... Read more
Related support groups: HIV Infection
Peers Best at Convincing High-Risk Individuals to Get HIV Test: Study
Posted 10 Oct 2014 by Drugs.com
FRIDAY, Oct. 10, 2014 – The best way to get people at high risk for HIV tested for the AIDS-causing virus is to have other high-risk people do the convincing, a new study suggests. This approach worked especially when the people doing the urging were paid for each high-risk person they successfully referred for testing, researchers reported. People who were contacted through this approach were 2.5 times more likely to be HIV-positive than those contacted through traditional counseling and referral programs. "A limitation of the traditional approach is that many people who are at high risk of HIV never take the initiative to get tested on their own," wrote study author Dr. Ryan Westergaard, an assistant professor of medicine at the University of Wisconsin School of Medicine and Public Health, in Madison. This lack of testing leads to higher numbers of people with HIV, the virus that ... Read more
Related support groups: HIV Infection, Diagnosis and Investigation
Less Than Half of HIV-Positive U.S. Hispanics Are Getting Proper Care
Posted 10 Oct 2014 by Drugs.com
THURSDAY, Oct. 9, 2014 – Even though Hispanics in the United States become infected with HIV at rates triple those of whites, less than half of Hispanics with the virus are receiving adequate treatment, a new report finds. The report, based on 2010 U.S. government health data, finds that while 80 percent of HIV-infected Hispanics do receive care soon after their diagnosis, only about 54 percent continue that care and only about 44 percent receive the virus-suppressing drugs they need to stay healthy. The researchers, led by epidemiologist Zanetta Gant of the U.S. Centers for Disease Control and Prevention (CDC), also found that only 37 percent of the more than 172,000 HIV-positive Hispanic adults in the United States have the virus under control. HIV is the virus that causes AIDS. The findings "underscore the need for enhanced linkage to care, retention in care, and viral suppression ... Read more
Related support groups: HIV Infection
2nd Baby 'Cured' of HIV Suffers Relapse
Posted 3 Oct 2014 by Drugs.com
THURSDAY, Oct. 2, 2014 – An Italian toddler thought cured of HIV with early aggressive treatment following birth has suffered a relapse, his doctors report. The 3-year-old child's viral levels of HIV rebounded two weeks after doctors took him off antiretroviral medications, according to a case report published Oct. 4 in The Lancet. The child's HIV levels had been undetectable since he was 6 months old, thanks to aggressive drug therapy that doctors started within 12 hours of his birth, doctors said. This is the second time that a child believed "cured" of HIV with early treatment has suffered a relapse once they stopped taking antiretroviral medication. In July, a 4-year-old Mississippi girl relapsed after living HIV-free for more than two years without medication. "What we've learned here is if you have an HIV-infected child who started treatment early, the fact that you have negative ... Read more
Related support groups: HIV Infection
HIV May Have Emerged in Congo in 1920s: Study
Posted 3 Oct 2014 by Drugs.com
THURSDAY, Oct. 2, 2014 – A new study into the origins of the AIDS virus suggests one strain of the disease appeared in the early 20th century in the western region of Congo and spread through a swath of Africa over the next several decades without notice by the rest of the world. The researchers say the findings support – but don't prove – the theory that the virus expanded its reach in Africa due to social factors such as railroad expansion, changing sexual habits and unsafe medical practices. The study adds to our understanding of "how a virus that is less transmissible than other pathogens like malaria and the common cold can still become established in the human population and eventually grow into a devastating pandemic," said study co-author Philippe Lemey, from the Rega Institute for Medical Research at Catholic University of Leuven, Belgium. "The fact that social changes were ... Read more
Related support groups: HIV Infection
FDA Approves Tybost (cobicistat) for use in the treatment of HIV-1 Infection
Posted 29 Sep 2014 by Drugs.com
September 24, 2014 – The U.S. Food and Drug Administration (FDA) has approved Tybost (cobicistat), a CYP3A inhibitor used in combination with atazanavir or darunavir for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Cobicistat is a pharmacokinetic enhancer that works by inhibiting the enzyme (CYP3A) that metabolizes atazanavir and darunavir. It increases the systemic exposure of these drugs and prolongs their effect. Cobicistat is also one of the ingredients in the combination HIV drug Stribild, which was approved by the FDA in August, 2012. Tybost comes in 150 mg tablets and is administered once daily in combination with the protease inhibitors atazanavir (Reyataz), or darunavir (Prezista). Because Tybost inhibits CYP3A, other medications metabolized by CYP3A may result in increased plasma concentrations and potentially severe side effects, which may be ... Read more
Related support groups: HIV Infection
FDA Approves Vitekta (elvitegravir) for HIV-1 Infection
Posted 29 Sep 2014 by Drugs.com
September 24, 2014 – The U.S. Food and Drug Administration (FDA) has approved Vitekta (elvitegravir), an integrase strand transfer inhibitor for the combination treatment of human immunodeficiency virus type 1 (HIV-1) infection in treatment-experienced adults. Elvitegravir is an HIV integrase strand transfer inhibitor that works by interfering with one of the enzymes that HIV needs to multiply. It is indicated in combination with an HIV protease inhibitor coadministered with ritonavir and with other antiretroviral drugs. It is one of the ingredients in the combination HIV drug Stribild, which was approved by the FDA in August, 2012. Vitekta (elvitegravir) comes in 85 mg and 150 mg tablets. It is administered once daily with food. The approval of Vitekta is based on the analyses through 96 weeks from one randomized, double-blind, active-controlled trial, Study 145, in ... Read more
Related support groups: HIV Infection
Half of HIV-Positive Gay Men in U.S. Aren't Getting Proper Treatment
Posted 26 Sep 2014 by Drugs.com
THURSDAY, Sept. 25, 2014 – Even though gay and bisexual men make up the majority of Americans infected with HIV, half aren't receiving ongoing care or getting the virus-suppressing drugs they need to stay healthy, a new report finds. The study, from the U.S. Centers for Disease Control and Prevention (CDC), looked at 2010 data on more than 400,000 male gay and bisexual Americans who were infected with HIV, the virus that causes AIDS. The research shows that while 77.5 percent did initially get HIV medical care within three months of their diagnosis, only about 51 percent continued getting care on an ongoing basis. Experts note that HIV infection can be manageable if powerful antiviral drugs are taken on a regular basis. But the CDC report finds that less than half of HIV-positive gay or bisexual men were prescribed such drugs, and only 42 percent achieved healthy "viral suppression." ... Read more
Related support groups: HIV Infection
California Trees Harbor Fungus Deadly to People With HIV
Posted 28 Aug 2014 by Drugs.com
THURSDAY, Aug. 28, 2014 – A potentially deadly fungus that has been sickening HIV/AIDS patients in Southern California for decades grows on trees, a new study finds. The team of scientists who published the research note that they were tipped off to the finding by a teen girl's science fair project. The Cryptococcus gattii fungus triggers infections of the lungs and brains and is responsible for a full third of all AIDS-related deaths, the researchers noted. They found that three tree species – Canary Island pine, Pohutukawa and American sweetgum – harbor the fungus and are sources of human infection. "Just as people who travel to South America are told to be careful about drinking the water, people who visit other areas like California, the Pacific Northwest and Oregon need to be aware that they are at risk for developing a fungal infection, especially if their immune system is ... Read more
Related support groups: HIV Infection, Fungal Infections
FDA Approves Triumeq (abacavir, dolutegravir and lamivudine) for the treatment of HIV-1 Infection
Posted 25 Aug 2014 by Drugs.com
August 22, 2014 – ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection.1 Triumeq is ViiV Healthcare’s first dolutegravir-based fixed-dose combination, offering many people living with HIV the option of a single-pill regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir, with the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine. Triumeq alone is not recommended for use in patients with current or past history of resistance to any components of Triumeq. Triumeq alone is not recommended in patients with resistance-associated integrase substitutions or clinically suspected INSTI resistance because the dose of dolutegravir in Triumeq is insufficient in these populations. Before i ... Read more
Related support groups: HIV Infection, Lamivudine, Abacavir, Dolutegravir
Ask a Question
Further Information
Related Condition Support Groups
Pre-Exposure Prophylaxis, Viral Infection
Related Drug Support Groups
Atripla, Truvada, Complera, Stribild, tenofovir, Viread, Kaletra, Norvir, lamivudine, view more... nevirapine, ritonavir, Reyataz, Sandoglobulin, Lexiva, efavirenz, Combivir, Norvir Soft Gelatin, Octagam, Epivir, Prezista, immune globulin intravenous, Flebogamma, Isentress, Privigen, Agenerase, Carimune, didanosine, Intelence, Fuzeon, Sustiva, Trizivir, Edurant, raltegravir, zidovudine, indinavir, abacavir, amprenavir, etravirine, nelfinavir, maraviroc, Zerit, Tivicay, Polygam S / D, stavudine, atazanavir, Retrovir, Carimune NF, Epzicom, Ziagen, emtricitabine, Triumeq, Tybost, Gammagard S / D, Vitekta, Venoglobulin-S 5%, Selzentry, abacavir / lamivudine, Zerit XR, Gammaplex, Telzir, Gamimune, Iveegam En, Panglobulin, Gammar-P IV, Gamimune N 5%, abacavir / lamivudine / zidovudine, Gamimune N 10%, Venoglobulin-S 10%, Viramune, rilpivirine, emtricitabine / nelfinavir / tenofovir, emtricitabine / lopinavir / ritonavir / tenofovir, emtricitabine / rilpivirine / tenofovir, cobicistat / elvitegravir / emtricitabine / tenofovir, abacavir / dolutegravir / lamivudine, dolutegravir, zalcitabine, tipranavir, lamivudine / zidovudine, fosamprenavir, lopinavir / ritonavir, enfuvirtide, saquinavir, emtricitabine / tenofovir, elvitegravir, cobicistat, Invirase, Fortovase, delavirdine, Aptivus, darunavir, Hivid, Viracept, Epivir-HBV, Rescriptor, efavirenz / emtricitabine / tenofovir, Videx, Videx EC, Crixivan, Emtriva, Panglobulin NF
